Open AccessIntensive blood pressure lowering reduces adverse cardiovascular outcomes among patients with high‐normal glucose: An analysis from the Systolic Blood Pressure Intervention Trial database
Author(s) -
Gong Yan,
Smith Steven M.,
Handberg Eileen M.,
Pepine Carl J.,
CooperDeHoff Rhonda M.
Publication year - 2018
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.13247
Subject(s) - medicine , blood pressure , sprint , confidence interval , hazard ratio , cardiology , adverse effect , physical therapy
The objective of this analysis is to determine the effect of intensive (<120 mm Hg) versus standard (<140 mm Hg) systolic blood pressure ( SBP ) targets on cardiovascular ( CV ) outcomes among SPRINT participants with low‐normal or high‐normal fasting glucose ( FG ). We categorized the 5425 SPRINT participants with FG <100 mg/ dL into 2 groups: <85 mg/ dL (low‐normal) and 85 to <100 mg/ dL (high‐normal). Among participants with low‐normal glucose, there was no significant difference in the primary outcome ( PO ) between the 2 treatment arms (adjusted hazard ratio, HR : 1.27 (95% confidence interval [ CI ] 0.68‐2.37, P = .46). However, the intensive SBP target was associated with 27% lower risk for the PO compared with the standard SBP target in those with high‐normal glucose ( HR 0.73, 0.57‐0.93, P = .01). Our results indicate that hypertensive patients with high‐normal FG may benefit from intensive SBP lowering, whereas benefits were inconclusive among those with low‐normal FG.